Radiation Oncology

Her2+   

Questions discussed in this category



The FDA recently approved neratinib based on data from the ExteNET trial; however, benefit appears modest and the risk of toxicity is not low.


Papers discussed in this category


J Clin Oncol, 2006 Sep 1